Navitoclax
Navitoclax (ABT-263) is a potent, orally bioavailable Bcl-2 family inhibitor with Ki of 350 nM) ; disrupts Bcl-2/Bcl-xL interactions with pro-death proteins (e.g., Bim), induces apoptosis, shows cellular activity against a panel of human tumor cell lines (EC50<1 uM) ; induces complete tumor regressions in xenograft models of NSCLA and ALL.Blood Cancer Phase 2 Clinical.
Product Specifications
CAS Number
923564-51-6
Product Name Alternative
ABT-263 | ABT 263 | ABT263
Purity
>98% (HPLC)
Solubility
10 mM in DMSO
Smiles
O=C (NS (=O) (C1=CC=C (N[C@H] (CCN2CCOCC2) CSC3=CC=CC=C3) C (S (=O) (C (F) (F) F) =O) =C1) =O) C4=CC=C (N5CCN (CC6=C (C7=CC=C (Cl) C=C7) CCC (C) (C) C6) CC5) C=C4
Molecular Formula
C47H55ClF3N5O6S3
Molecular Weight
974.6127
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
Benzamide, 4-[4-[[2- (4-chlorophenyl) -5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[ (1R) -3- (4-morpholinyl) -1-[ (phenylthio) methyl]propyl]amino]-3-[ (trifluoromethyl) sulfonyl]phenyl]sulfonyl]-
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
